Fresenius SE & Co KGaA (FREG.DE)
94.28EUR
7:35am EDT
€-0.42 (-0.44%)
€94.70
€94.19
€95.04
€93.39
213,409
396,091
€99.91
€78.12
FREG.DE
About
Overall
| Beta: | 0.47 |
| Market Cap (Mil.): | €16,893.61 |
| Shares Outstanding (Mil.): | 178.39 |
| Dividend: | 1.10 |
| Yield (%): | 1.16 |
Financials
| FREG.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.37 | 72.70 | 30.65 |
| EPS (TTM): | 5.15 | -- | -- |
| ROI: | 9.22 | 4.63 | 18.83 |
| ROE: | 12.67 | 9.75 | 19.74 |
RPT-Fitch Affirms Fresenius at 'BB+'; Outlook Revised to Positive
June 17 - (The following statement was released by the rating agency)
Rhoen says renewed takeover attempt not a given
FRANKFURT, June 13 - Rhoen-Klinikum cautioned that a shareholder vote that removed a major barrier against a takeover of the German hospital operator would not necessarily lead to a new bid from one-time suitor Fresenius .
UPDATE 1-Rhoen shareholders vote to scrap takeover hurdle
* Removal of hurdle could lure back one-time bidder Fresenius
Fresenius eyes more hospital deals in Germany
FRANKFURT, May 17 - German diversified healthcare group Fresenius will look for further takeovers to underpin its position as Germany's largest private-sector hospitals operator, its chief executive said.
Fresenius SE eyes small and mid-sized acquisition targets-paper
FRANKFURT, May 11 - German diversified healthcare group Fresenius SE has identified potential takeover targets costing up to 300 million euros ($389 million), Chief Executive Ulf M. Schneider told German weekly paper Euro am Sonntag.
Rhoen says shareholder to challenge 90 pct acceptance hurdle
FRANKFURT, May 10 - Rhoen-Klinikum said that shareholder Alecta, a Swedish pension firm, is seeking to challenge the minimum shareholder approval of 90 percent that is required for major strategic decisions at the German hospitals operator.
BRIEF-Fresenius shares down 1.8 pct after Q1 results
FRANKFURT, April 30 - Fresenius : * Shares down 1.8 percent after Q1 results
CORRECTED-Fresenius earnings below consensus on healthcare cuts
(Corrects second paragraph to show Q1 adj net income was 224 mln eur, not 223 mln)
Regulator okays Asklepios purchase of Rhoen shares -sources
FRANKFURT, March 14 - German antitrust regulators approved plans by hospital operator Asklepios to take a blocking minority of more than 10 percent in rival Rhoen-Klinikum under certain conditions, two people familiar with the transaction said.
UPDATE 2-Resilient Fresenius boosts payout policy
* FMC's 2013 profit outlook more cautious than market view
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Finlabo SIM Spa
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$495.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
